The SELECT trial showed that semaglutide reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in adults with obesity and established cardiovascular disease, without requiring a diabetes diagnosis. The FLOW trial showed kidney benefits with semaglutide use in patients with type 2 diabetes and chronic kidney disease. Improvements in hard clinical outcomes like cardiac events, kidney disease, and death are commonly observed with GLP-1 use, and are due to both the direct effects of treating the obesity, and indirect effects of the medications themselves
R., Folmes, C
It was a pre-approval cardiac safety assessment trial with a primary objective of non-inferiority to placebo, which was basically done to get early approval as per regulatory guidance
What to consider when choosing a peptide for hair growth Not all peptides or hair products were made the same, but how do you tell the best from the rest
Because of this fact, the major part of the destructive process is considered to be extravascular , within macrophages of the spleen and, to a lesser extent, the liver and bone marrow
